Skip to main
TMCI
TMCI logo

TMCI Stock Forecast & Price Target

TMCI Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 20%
Buy 0%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

Treace Medical Concepts Inc. exhibits a promising outlook driven by the potential for increased sales of its ancillary products, which could lead to higher revenue per procedure than currently modeled. The company's innovative systems, particularly the new minimally invasive (MIS) Osteotomy system, are anticipated to gain better market traction, further supporting financial growth. Additionally, there is a growing expectation for a significant acceleration in growth starting in the second half of 2025, indicating a positive financial trajectory for the company.

Bears say

Treace Medical Concepts faces significant challenges due to potential pricing pressures on its Lapiplasty procedure, which could negatively impact financial projections and overall revenue estimates. Additionally, if the profitability of Lapiplasty for providers is perceived as less favorable compared to alternative bunionectomy procedures, it may hinder the adoption rate among physicians and healthcare facilities. These factors contribute to a cautious outlook on the company's financial performance as they indicate vulnerabilities in its market positioning and competitive advantages.

TMCI has been analyzed by 5 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 0% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Treace Medical Concepts (TMCI) Forecast

Analysts have given TMCI a Hold based on their latest research and market trends.

According to 5 analysts, TMCI has a Hold consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Treace Medical Concepts (TMCI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.